PROM1 and non-small cell lung carcinoma: Different researchers demonstrated that CD133+ cells derived from NSCLC patients expressed high tumorigenic activity, enhanced levels of different stemness genes, high resistance to cisplatin, and self-renewal capacity [100,101].